SecBot SecBot
DEFA14A ·Filed Apr 24, 2026

APGE

Apogee Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-177401
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the company's 10-Q filing for any guidance revisions or disclosures related to the recent board changes. The resignation of two directors may signal governance shifts, but this proxy filing itself is routine.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$86.47
T+0 close · Apr 24, 2026 · via day close
Latest settled
+55.06%
T+60 · $134.08
Vs SPY
+50.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $86.47entry
  2. T+1 · 7mo ago −1.27%α −0.79% · $85.37
  3. T+5 · 7mo ago −3.38%α −3.78% · $83.55
  4. T+20 · 6mo ago −4.23%α −9.19% · $82.81
  5. T+60 · 4mo ago +55.06%α +50.28% · $134.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics is holding its annual shareholder meeting to vote on the re-election of three Class III directors, ratification of its auditor, and advisory approval of executive compensation. This routine proxy filing follows recent board resignations, suggesting potential governance changes, but the filing itself contains no new material information.

Key Financial Metrics

Vote
director election
Meeting
2026-06-09
Seats Contested
3

Key Facts

  • Annual shareholder meeting to vote on re-election of three Class III directors: Mark C. McKenna, Jennifer Fox, and William (BJ) Jones, Jr.
  • Vote to ratify Ernst & Young LLP as independent auditor.
  • Advisory vote to approve compensation of named executive officers.
  • Recent context: Two board members resigned effective May 11, 2026, just prior to this proxy filing.

Financial Impact

No material financial figures disclosed in this proxy statement.

Risk Factors

  • Potential for governance instability following the resignation of two board members.
  • No immediate financial risk indicated by this proxy filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-177401
Document: 0001193125-26-177401-index-headers.html0001193125-26-177401
Document: 0001193125-26-177401-index.html0001193125-26-177401
Document: 0001193125-26-177401.txt0001193125-26-177401

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens in 8h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026